共 98 条
- [11] Lefkowitz MP(2010)The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis J Card Fail 380 1387-1395
- [12] Rizkala AR(2012)The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 52 997-1003
- [13] Fox K(2008)Prognostic value of changes in N-terminal pro-brain natriuretic peptide in val-HeFT (valsartan heart failure trial) J Am Coll Cardiol 27 65-75
- [14] Ford I(2006)Predictors of mortality and morbidity in patients with chronic heart failure Eur Heart J 372 817-821
- [15] Steg PG(2008)Heart rate as a prognostic risk factor in patients with coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial Lancet 5 e003221-402
- [16] Tendera M(2016)Cost‐effectiveness of ivabradine for heart failure in the United States Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 4 392-797
- [17] Ferrari R(2016)Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction JACC Heart Fail. 371 796-undefined
- [18] Swedberg K(2014)Updating cost-effectivenes —the curious resilience of the $50,000-per-QALY threshold N Engl J Med undefined undefined-undefined
- [19] Komajda M(undefined)undefined undefined undefined undefined-undefined
- [20] Bohm M(undefined)undefined undefined undefined undefined-undefined